Compare Bactiguard Holding AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 573 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.28
-2.49%
1.82
Revenue and Profits:
Net Sales:
63 Million
(Quarterly Results - Dec 2025)
Net Profit:
13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.95%
0%
-14.95%
6 Months
-19.12%
0%
-19.12%
1 Year
-44.07%
0%
-44.07%
2 Years
-76.92%
0%
-76.92%
3 Years
-79.11%
0%
-79.11%
4 Years
-83.6%
0%
-83.6%
5 Years
-90.32%
0%
-90.32%
Bactiguard Holding AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.62%
EBIT Growth (5y)
9.80%
EBIT to Interest (avg)
-3.44
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.27
Sales to Capital Employed (avg)
0.45
Tax Ratio
22.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.00
EV to EBIT
-31.10
EV to EBITDA
28.93
EV to Capital Employed
1.78
EV to Sales
2.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-5.72%
ROE (Latest)
-5.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
63.20
45.50
38.90%
Operating Profit (PBDIT) excl Other Income
23.30
3.30
606.06%
Interest
2.20
2.60
-15.38%
Exceptional Items
0.00
0.00
Consolidate Net Profit
12.50
-7.50
266.67%
Operating Profit Margin (Excl OI)
183.30%
-184.50%
36.78%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 38.90% vs -5.60% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 266.67% vs 7.41% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
215.90
241.70
-10.67%
Operating Profit (PBDIT) excl Other Income
37.70
5.30
611.32%
Interest
12.20
15.60
-21.79%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.80
-29.80
73.83%
Operating Profit Margin (Excl OI)
-43.50%
-166.30%
12.28%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -10.67% vs 19.95% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 73.83% vs 78.47% in Dec 2024
About Bactiguard Holding AB 
Bactiguard Holding AB
Pharmaceuticals & Biotechnology
Bactiguard Holding AB is a Sweden-based company engaged in the development of solutions for preventing of device-related healthcare associated infections (HAI). Its technology is based on the Bactiguard Infection Protection (BIP), a thin coating permanently bound to the surface of medical devices. It consists of the noble metals: gold, palladium and silver, which reduces the adhesion of bacteria to the coated surfaces. Its product portfolio includes: BIP Foley Catherer, made from medical grade latex, and BIP Foley Catheter - Silicone, used for drainage and irrigation of the bladder; BIP Endotracheal Tube, for general anesthesia, intensive care, and emergency medicine for airway management and mechanical ventilation; and BIP Central Venous Catherer, made of polyurethane and used to administer drugs and intravenous solutions, monitor pressure and blood sampling. The Company is also present in Portugal, via a distribution agreement with Socime Medical Ltd, and Zambia.
Company Coordinates 
Company Details
Biblioteksgatan 25 , STOCKHOLM None : 114 35
Registrar Details






